Compliance with medications lowers health care costs

October 23, 2006

Patients with inflammatory bowel disease (IBD) who take medications as directed have decreased medical costs, researchers from the University of Chicago researchers report at the American College of Gastroenterology annual scientific meeting in Las Vegas. A second study from the same group, however, suggests that there is no simple way to improve compliance.

In the first study, patients with mild to moderate ulcerative colitis who consistently took their medications -- in this case 5-aminosalicyclic acid (5-ASA) -- incurred 12.5 percent lower medical costs than those who did not.

"Patients with ulcerative colitis often struggle to comply with current 5-ASA treatments because they have to take multiple pills throughout the day," said study director Sunanda Kane, M.D., associate professor of medicine at the University of Chicago. "This study shows that following your doctor's advice, even when it's inconvenient, is worth the extra effort."

Using data from the from the Maryland CareFirst BlueCross BlueShield database, the researchers followed the progress of hundreds of patients who were new users of 5-ASA for an average of 332 days.

To determine which patients were most compliant and how that affected costs, the researchers compared data on prescription refills, costs and outcomes from 4,947 pharmacy and medical claims from 2002 through 2004. Patients who refilled their prescriptions within 15 days of the instructed date and did not switch to another drug were considered consistently compliant.

"We learned two things," said Kane. "First, compliance was poor overall, and second, compliance matters."

Compliance was "unimpressive" in all groups, she said, "and patients pay the price in terms of worse health and increased costs of care."

Compliance rates were similar for males and females, but the old and the young scored poorly. Fifty-seven percent of patients between 40 and 64 met the standard, followed by 55 percent for those between 18 and 40. For those over 65, compliance fell to 41 percent and for those under 18, to 35 percent.

Non-compliance resulted in higher total healthcare costs for all types of medical services. Costs were 32 percent higher for inpatient services and 44 percent for outpatient costs.

"What if we could simplify a patient's regimen with a reduced pill burden, ideally a once-daily treatment?" Kane and colleagues wondered. "Would patients be more likely to comply, and would that lower health care expenses?"

She is currently testing that theory in a study of once-daily 5-ASA.

While the impact of a once-daily regimen on compliance is being studied, a second report from Kane and colleagues, however, suggests that improving compliance will require much more than simply reducing the pill count. When they studied prescription refills among 1,680 patients with ulcerative colitis, they found that the number of prescribed pills per day had no effect on compliance.

The researchers followed patients on one of four slightly different regimens - none of them once a day -- that involved taking 4, 6, 9 or 16 pills a day.

All four groups had steadily declining compliance for the first three months. Compliance, as measured by prescription refill rates, decreased by about twelve percent per month for the first three months, falling from 100 percent at the beginning to about 65 percent after three months. After three months they leveled off, decreasing only by about one percent per month for the next nine months.

"What it all means," Kane said, "is that we have a lot more to learn about patient behaviors and motivations."
-end-
The cost study was funded by Shire Pharmaceuticals and the dosing study by the Procter & Gamble Company.

University of Chicago Medical Center

Related Inflammatory Bowel Disease Articles from Brightsurf:

People with inflammatory bowel disease still die earlier despite increase in life
A study comparing life expectancy of people with inflammatory bowel disease (IBD) and without found that, while life expectancy increased for both groups, people with IBD generally died sooner.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Team develops wearable sensor to help people with inflammatory bowel disease
University of Texas at Dallas researchers have designed a wearable device that monitors sweat for biomarkers that could signal flare-ups of inflammatory bowel disease (IBD).

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Yes, inflammatory bowel disease and celiac disease are linked
A systematic review and meta-analysis that has determined there is a nine-fold increased risk of having IBD for patients with a previous diagnosis of celiac disease.

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.